CSL Behring is a global biotech leader specializing in the research, development, and manufacturing of life-saving biotherapies, including immunoglobulins and plasma protein products, for patients with rare and serious diseases. The company has a long history of successful R&D operations in Switzerland and has cultivated valuable collaborations with Swiss academic institutions like the Swiss Federal Institute of Technology Lausanne (EPFL) and Lausanne University Hospital (CHUV). The move to Lausanne is a strategic next step for CSL Behring, aiming to extend its long-standing corporate partnership with the Biopôle campus.
Since its establishment in 2009, the Biopôle campus has evolved into one of the most vibrant biotech hubs in Switzerland. Over 130 companies and research organizations currently operate across eight buildings, with five more under construction. Biopôle offers a range of office and lab spaces to accommodate the needs of its community, providing co-working, private, and serviced options. CSL Behring’s decision to open an office on the campus further expands its access to the thriving ecosystem and unparalleled talent pool.
CSL Behring, which has been researching and manufacturing in the canton of Bern for over 30 years with more than 1,500 employees, has also been a corporate partner of Biopôle SA since 2020, enjoying special access to its innovative community of life sciences start-ups. The new office in Lausanne will allow CSL Behring to further integrate into the Biopôle community and capitalize on the dynamic innovation within the campus.
Adrian W. Zuercher, CSL Behring’s Vice President, Head Research Europe and Global Head Plasma Protein Research, highlighted the importance of the move: “Switzerland is an ideal place for us to develop our R&D presence, given its high density of biotech organizations per capita. Biopôle is at the heart of this thriving ecosystem, and its excellent talent pool offers us vast opportunities for collaboration.”
